ASX/News Release

AVITA MEDICAL LIMITED (ASX: AVH)
Cleansing Notice under section 708A of the Corporations Act 2001 (Cth)

Valencia, Calif., USA, and Melbourne, Australia, 14 June 2018: On 6 June 2018, Avita Medical Limited ACN 058 466 523 (**Company**) announced that it had received commitments for a placement of $16 million worth of fully paid ordinary shares in the Company at an issue price of $0.050 per share to international and Australian institutional and sophisticated investors with the placement to occur in two tranches (**Placement**). The first tranche of the Placement for $12.77 million worth of fully paid ordinary shares occurred on 12 June 2018 (**Tranche 1 of the Placement**).

The Company gives this Notice under section 708A(5)(e) of the *Corporations Act 2001 (Cth)* (**Corporations Act**). The shares the subject of Tranche 1 of the Placement were issued without disclosure to investors under Part 6D.2 of the Corporations Act.

As at the date of this Cleansing Notice, the Company has complied with:

- the provision of Chapter 2M of the Corporations Act as they apply to the Company; and
- section 674 of the Corporations Act.

As at the date of this Cleansing Notice, there is no excluded information for the purposes of section 708A(7) and section 708A(8) of the Corporations Act.

ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical's patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient's own skin. Our medical devices work by preparing a REGENERATIVE EPITHELIAL SUSPENSION™, an autologous suspension comprised of the patient's own skin cells and wound healing factors that are necessary to regenerate natural healthy skin. This autologous suspension is then sprayed onto the areas of the patient to be treated.

In the United States, the RECELL Device is an investigational device limited by federal law to investigational use. In September 2017, AVITA Medical submitted to the U.S. Food and Drug Administration (FDA) a PreMarket Approval (PMA) application for RECELL for the treatment of burn injuries.

In all countries outside of Europe, our portfolio is marketed under the RECELL Device brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. RECELL Device is TGA-registered in Australia, and CFDA-cleared in China.

In Europe, our portfolio of medical device products received CE-mark approval as three tailored product presentations, with three individual brand names. RECELL Device is designed for the treatment of burns and plastic reconstructive procedures; REGENERCELL™ Autologous Cell Harvesting Device has been formulated for chronic wounds including leg and foot ulcers; and RENOVACELL™ Autologous Cell Harvesting Device is tailored for aesthetic applications including the restoration of pigmentation.

To learn more, visit www.avitamedical.com.

FOR FURTHER INFORMATION:

OUS Media **Monsoon Communications** Sarah Kemter Phone: +61 (0)3 9620 3333 Mobile: +61 (0)407 162 530 sarahk@monsoon.com.au **US Media** **Syneos Health Public Relations** David Polk Phone: +1 (310) 309 1029 Mobile +1 (805) 428 5775 david.polk@syneoshealth.com	**Investors:** **Westwicke Partners** Caroline Corner Phone +1 (415) 202-5678 caroline.corner@westwicke.com **AVITA Medical Ltd** Dale A. Sander Chief Financial Officer Phone +1 (858) 663-6993 dsander@avitamedical.com